Ukrainian Journal Health of Woman. 2025. 5(180): 54-60. doi: 10.15574/HW.2025.5(180).5460
Biduchak A. S.¹, Chornenka Zh. A.¹, Yasinska E. Ts.¹, Hopko N. V.², Myroniuk М. B.^2
1Bukovynian State Medical University, Chernivtsi, Ukraine
²SI «Chernivtsi Oblast Center for Disease Control and Prevention of the Ministry of Health of Ukraine»

For citation: Biduchak AS, Chornenka ZhA, Yasinska ETs, Hopko NV, Myroniuk МB. (2025). Women's screening: standards, recommendations, benefits. Ukrainian Journal Health of Woman. 5(180): 54-60. doi: 10.15574/HW.2025.5(180).5460
Article received: Jun 29, 2025. Accepted for publication: Oct 30, 2025.

Women's health is a strategic indicator of the state of public health, demographic stability and socio-economic development of society. It determines not only fertility and life expectancy indicators, but also forms the basis for the sustainable development of the state and the well-being of future generations. Given the global trends of population aging, urbanization and lifestyle changes, the preventive focus of medical care is gaining priority. In the context of the growing prevalence of chronic non-communicable, oncological, endocrine, and metabolic diseases, preventive measures aimed at early detection of pathology are becoming particularly relevant. Women's health screening as a system of periodic examinations allows for the diagnosis of diseases at preclinical stages, reducing mortality and improving the quality of life. At the same time, the level of coverage of screening programs remains insufficient due to low awareness of the population, socio-economic barriers and organizational difficulties in the functioning of the healthcare system.
Aim – to analyze modern standards of female screening, summarize international and national recommendations for preventive examinations and determine their role in increasing the effectiveness of early diagnosis and reducing morbidity and mortality rates.
The study is analytical and review in nature. Scientific publications, clinical guidelines and regulatory documents for 2019-2025 were analyzed. Methods of systemic, comparative and general analysis were used, taking into account age characteristics, individual risk factors and the possibilities of adapting international standards to the national context. It was established that female screening covers oncological, cardiovascular and metabolic, gynecological, hormonal, osteoporotic, and infectious areas. Regular cytological and HPV testing, mammography, as well as monitoring of blood pressure, glycemia and lipid profile ensure timely detection of pathological changes and prevention of complications. For Ukraine, it is relevant to implement a risk-oriented comprehensive screening algorithm integrated into the primary health care system, with subsequent monitoring and increasing women's adherence to preventive examinations.
Conclusion. Women's screening is an effective prevention tool that requires improving organizational mechanisms, strengthening educational work and an individualized approach at different stages of a woman's life.
The authors declare no conflicts of interest.
Keywords: women's screening, prevention, early diagnosis, cancer prevention, cardiovascular diseases, metabolic disorders, standards.

REFERENCES

1. Aguiar-Ibáñez R, Mbous Y, Sharma S, Chakali R, Chawla E. (2025). Barriers to cancer screening uptake and approaches to overcome them: a systematic literature review. Front Oncol. 15: 1575820. https://doi.org/10.3389/fonc.2025.1575820; PMid:40842583 PMCid:PMC12364675

2. Bernstein E, Lev-Ari S, Shapira S, Leshno A, Sommer U, Al-Shamsi H et al. (2023). Data From a One-Stop-Shop Comprehensive Cancer Screening Center. J Clin Oncol. 41(14): 2503-2510. https://doi.org/10.1200/JCO.22.00938; PMid:36669135

3. Gavinski K, DiNardo D. (2023). Cervical Cancer Screening. Med Clin North Am. 107(2): 259-269. https://doi.org/10.1016/j.mcna.2022.10.006; PMid:36759096

4. Hijrah H, Usman AN, Sanusi Baso Y, Syarif S, Ahmad M, Nulandari Z. (2024). Influence of variables on breast self-examination: Potential barrier or enhancement of breast cancer prevention. Breast Disease. 43(1): 145-155. https://doi.org/10.3233/BD-249001; PMid:38820008 PMCid:PMC11191488

5. Karavska A, Kizub D, Dzhemiliev A, Wanis K, Vus V, Kopetskyi V et al. (2024). Fac-tors Affecting Breast Cancer Screening in Ukraine. JCO Glob Oncol. 10(1): 75-76. https://doi.org/10.1200/GO-24-65000

6. Lebedyuk VV. (2024). Management of patients with abnormal screening results and precancerous conditions of the cervix according to national standards 2024 (clinical case). Ukrainian Journal Health of Woman. 6(175): 83-88. https://doi.org/10.15574/HW.2024.6(175).8388

7. Mills JM, Morgan JR, Dhaliwal A, Perkins RB. (2021). Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort. Gynecol Oncol. 162(2): 308-314. https://doi.org/10.1016/j.ygyno.2021.05.035; PMid:34090706

8. Mondragón Márquez LI, Domínguez Bueso DL, González Ruiz LM, Liu JJ. (2023). Associations between sociodemographic factors and breast, cervical, and colorectal cancer screening in the United States. Cancer Causes Control. 34(12): 1073-1084. https://doi.org/10.1007/s10552-023-01758-z; PMid:37486400

9. Narayan AK, Miles RC, Woods RW, Spalluto LB, Burnside ES. (2024). Methodological Considerations in Evaluating Breast Cancer Screening Studies. J Breast Imaging. 6(6): 577-585. https://doi.org/10.1093/jbi/wbae038; PMid:39096512

10. Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, Davis EM et al. (2025). Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 333(6): 498-508. https://doi.org/10.1001/jama.2024.27154; PMid:39808425

11. Ponzel NI. (2025). Validation of the Ukrainian questionnaire "Assessment of Patient Readiness for Breast and Cervical Cancer Screening". Family Medicine. European practices. 2: 54-58. https://doi.org/10.30841/2786-720X.2.2025.331927

12. Radzishevska YeB, Sukhina OM, Vasylyev LYa, Sukhin VS, Nemaltsova KV, Hranovska HI et al. (2024). Determination of risk factors for the occurrence of recurrences, metastases, and somatic complications after treatment of locally advanced cervical cancer using modern information technologies. Ukrainian journal of radiology and oncology. 32(4): 478-490. https://doi.org/10.46879/ukroj.4.2024.478-490

13. Rajaram S, Gupta B. (2021). Screening for cervical cancer: Choices & dilemmas. Indian J Med Res. 154(2): 210-220. https://doi.org/10.4103/ijmr.IJMR_857_20; PMid:34854432 PMCid:PMC9131755

14. Sabatino SA, Thompson TD, White MC, Villarroel MA, Shapiro JA, Croswell JM et al. (2023). Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021. Prev Chronic Dis. 20: E94. https://doi.org/10.5888/pcd20.230071; PMid:37884318 PMCid:PMC10625435

15. Sahasrabuddhe VV. (2024). Cervical Cancer: Precursors and Prevention. Hematol Oncol Clin North Am. 38(4): 771-781. https://doi.org/10.1016/j.hoc.2024.03.005; PMid:38760198

16. Salingaros S, Shieh Y, Finkel ML, Polaneczky M, Korenstein D, Marti JL. (2024). Public cervical cancer screening recommendations from US cancer centers: Assessing adherence to national guidelines. J Med Screen. 31(3): 201-204. https://doi.org/10.1177/09691413241238960; PMid:38504656

17. Sefuthi T, Nkonki L. (2022). A systematic review of economic evaluations of cervical cancer screening methods. Syst Rev. 11(1): 162. https://doi.org/10.1186/s13643-022-02017-z; PMid:35945642 PMCid:PMC9361672

18. Serrano B, Ibáñez R, Robles C, Peremiquel-Trillas P, de Sanjosé S, Bruni L. (2022). Worldwide use of HPV self-sampling for cervical cancer screening. Prev Med. 154: 106900. https://doi.org/10.1016/j.ypmed.2021.106900; PMid:34861338

19. Shami S, Coombs J. (2021). Cervical cancer screening guidelines: An update. JAAPA. 34(9): 21-24. https://doi.org/10.1097/01.JAA.0000769656.60157.95; PMid:34448772

20. Simms KT, Keane A, Nguyen DTN, Caruana M, Hall MT, Lui G et al. (2023). Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nat Med. 29(12): 3050-3058. https://doi.org/10.1038/s41591-023-02600-4; PMid:38087115 PMCid:PMC10719104

21. Svintsitskyi VS, Pryimak VV, Renkas OP. (2020). Modern approaches of the diagnostics and treatment of cervical cancer. Ukrainian Medical Journal. 2(3): 1-7. https://doi.org/10.32471/umj.1680-3051.137.178064

22. Tokar P. (2025). Indicators of primary detection, staging and dispensary registration of cervical cancer in Ukraine (2014-2023): epidemiological and regional analysis. Health & Education. 3: 90-100. https://doi.org/10.32782/health-2025.3.10

23. Viveros-Carreño D, Fernandes A, Pareja R. (2023). Updates on cervical cancer prevention. Int J Gynecol Cancer. 33(3): 394-402. https://doi.org/10.1136/ijgc-2022-003703; PMid:36878567

24. Yezhova IE, Volodko NA. (2025). Clinical, morphological and molecular markersin the formation of prognosis in patientswith cervical cancer: literature review. Reproductive endocrinology. 6: 43-58. doi: 10.18370/2309-4117.2025.81.43-58.

25. Zafar N, Wolf AB, Kepniss JL, Teal AC, Brem RF. (2024). Effectiveness of Community Education for Breast Cancer Screening. J Breast Imaging. 6(2): 166-174. https://doi.org/10.1093/jbi/wbae002; PMid:38412358